Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness

Mohsen Rokni¹*, Kazem Ahmadikia²*, Somaye Asghari³, Shahabodin Mashaei⁴ and Fahimeh Hassanali⁵

Abstract

Background: Since December 2019, when a cluster of pneumonia cases due to SARS-CoV-2 initially emerged in Wuhan city and then rapidly spread throughout the world, the necessity for data concerning the clinical and para-clinical features of Iranian patients with COVID-19 was highlighted. Therefore, we aimed to compare the clinical, para-clinical and laboratory evidences of deceased patients with survival group.

Methods: We extracted data regarding 233 patients with laboratory-confirmed COVID-19 from Buali Hospital in Iran; clinical/para-clinical and inflammatory indexes data were collected and analyzed. The data of laboratory examinations and chest CT findings were compared between deceased and survived patients.

Results: The mean age of the patients was 49.8 years and 64% of our patients were male. The acute respiratory distress syndrome occurred in 64 patients, 52 who were admitted to the ICU, which all of them underwent invasive mechanical ventilation, and 28 who died. Lymphopenia (79%), neutrophilia (79%), and thrombocytopenia (21%) were the most frequently observed laboratory findings of the deceased group on admission. Most patients (68%) had a high systematic immune-inflammation (SII) index of > 500 and increased C-reactive protein level (88%). Levels of inflammatory indexes such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and SII were documented to be significantly elevated in the deceased group when compared with the patients who survived ($P < 0.0001$, $P < 0.001$, $P < 0.0001$, respectively). The most commonly presented symptoms were fever (70%) and cough (63%) on admission. Headache was uncommon (11%). Ground-glass opacity with consolidation (mixed) was the most common radiologic finding on chest CT (51%). No radiographic or CT abnormality was found in 15 of 204 patients (7%).

(Continued on next page)
Background

In late December 2019, a cluster of unknown pneumonia cases reported in Wuhan, China. A few days later, the causative agent of this mysterious pneumonia was recognized as a novel betacoronavirus. Subsequently, The causative virus called as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the relevant disease termed as corona virus disease 2019 (COVID-19) by the World Health Organization (WHO) [1, 2]. At present, the cases of COVID-19 have been detected in many countries around the world. According to the latest data, up to the Aug 30, 2020, the numbers of laboratory-confirmed cases in Iran reached 371,816 of which 21,359 were unfortunately deceased, and 321,421 were recovered. Also 3759 were severe illness. The number of laboratory-confirmed cases in other countries also reached 24,854,140 of which 838,924 were died, according to official data from the WHO.

Many previous studies have shown that COVID-19 patients have significant inflammatory responses, accompanied by a decrease in the absolute count of lymphocytes in the peripheral blood circulation and an enhancement in the number of neutrophils [3]. Mild/moderate form of SARS-CoV-2 infection is the major clinical form of the infection that is characterized by fever, malaise, cough, upper respiratory symptoms, and with or without dyspnea. Therefore, most of these patients do not need hospitalization [4]. However, nearly 15–20% of cases, who show prominent abnormalities in laboratory findings predicting disease deterioration, would develop severe form of the disease which majorly need to be intensively cared and hospitalization in intensive care unit (ICU) [5, 6]. Organ dysfunction including acute respiratory distress syndrome (ARDS), shock, acute cardiac injury and acute renal injury, may occur in 5% of severe cases with COVID-19 [4, 7]. Since, majority of COVID-19 patients show lung involvement on computed tomography (CT) scan imaging patterns, radiological (X ray) examinations have become essential diagnostic method in early detection and assessment of disease progression [8]. Typical chest CT scan findings of COVID-19 include peripherally distributed multifocal ground-glass opacities (GGOs) with patchy consolidations and posterior part or lower lobe involvement pre-dilection [9]. Increasing numbers of pulmonary lesions extent and density of GGOs on CT scan show disease progression [7, 9]. The pathological damages caused by the virus could stimulate a series of inflammatory responses and uncontrolled production of inflammatory cytokines e.g. interleukin (IL)-1, IL-6 and TNF-α, the recruitment of inflammatory macrophages and granulocytes, leading to cytokines storm (CSS), termed as a secondary hemophagocytic lymphohistiocytosis (sHLH) or macrophage activation syndrome, which may follow by disease deterioration, ARDS, septic shock and eventually multiple organ system failure (MOSF) in some patients [10]. Various studies suggested that genes polymorphisms (SNP) of inflammatory interleukin and chemokine are likely associated with genetic susceptibility to SARS-CoV-2, and probably is responsible for developing different form of COVID-19 in different individuals [11, 12].

In this study, we compared the clinical/laboratory findings, imaging manifestation and outcomes of the disease in clinically classified groups including non-severe and severe (consequently death) COVID-19 patients, to find potential prognostic indications contributing to an accurate assessment of the COVID-19 severity.

Methods

Design and Participants

This cross-sectional study was performed in referral hospital for COVID-19 patients in Zahedan, Iran. Clinical and paraclinical data regarding 233 laboratory confirmed cases of COVID-19 who were hospitalized in our hospital from February 29, 2020 to May 24, 2020 were subjected in the analysis. A verified case of COVID-19 was defined as a positive result on real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of naso-pharyngeal or oro-pharyngeal swab specimens. The protocol of the present study was approved by the ethical committee of ZAUMS, and written consent was obtained from the patients or their guardians. The criteria of clinically based classification of our subjects were as follows, mild/moderate (non-severe) form characterizing with the respiratory distress or oxygen saturation ≤ 93%, or severe form if at least one of the following conditions presented: SpO₂ ≤ 90%, if respiratory failure occurred and mechanical ventilation was
required, shock occurred or ICU admission was required.

Data collection
From all suspected patients with SARS-CoV-2 infection that were admitted to be hospitalized in infectious unit, oro- and naso-pharyngeal swab specimens were collected and stored in virus transport medium (VTM). In addition, fasting venous blood specimen was collected for para-clinical assessment.

For all of the patients, routine blood biochemistry parameters, complete cell blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and chest radiological/CT scan were performed. Routine blood biochemistry analyses included liver function test (LFT), renal function, electrolytes test, lactate dehydrogenase (LDH), myocardial enzymes e.g. creatine phosphokinase (CPK), D-Dimer and status of other virus infection.

Real-time reverse transcription polymerase chain reaction assay
Viral ribonucleic acid was extracted from the oro- and naso-pharyngeal swab samples using the COVID-19 ORF1ab/N (two regions, so four sequences of primer should be presented) gene nucleic acid detection kit (manual).

Real-time RT-PCR assays for SARS-CoV-2 RNA detection were performed using Quanti Nova Probe RT-PCR Kit (Qiagen) in a Light Cycler 480 Real-Time PCR System (Roche, Basel, Switzerland) as previously described [13]. Each 20 μl reaction mixture contained 10 μl of 2 × Quanti Nova Probe RT-PCR Master Mix, 0.2 μl of QN Probe RT-Mix, 1.6 μl of each 10 μM forward and reverse primer, 0.4 μl of 10 μM probe, 1.2 μl of RNase-free water and 5 μl of RNA as the template. The thermal cycling condition was 10 min at 45 °C for reverse transcription, 5 min at 95°C for PCR initial activation, and 40 cycles of 94°C for 10 s and 58°C for 30 s. According to the cycle threshold (Ct) analysis, if the Ct values of the fluorescein amidites (FAM) channel and victoria (VIC) channel were ≤ 37, and the curve is S-shaped with a significant exponential growth period, the test result specimen regarded as positive, if the Ct value of one channel was ≤ 37, the specimen tested again. If the Ct values of both channels are > 37, and the internal standard channel test result was positive, then the test result specimen regarded as negative.

Inflammatory indications
Inflammatory indexes were detected using specific parameters of blood analysis. These indexes were as follows: neutrophil to lymphocyte ratio (NLR) by dividing the neutrophil absolute count to the lymphocyte absolute count and platelet to lymphocyte ratio (PLR) by dividing the platelet count to the lymphocyte absolute count were defined. Systematic immune-inflammation index (SII) was calculated as follows: platelet count × NLR (per μL).

Statistics analysis
All of the data presented by mean ± standard error of mean (SEM). Analysis was performed with the IBM SPSS version 23.0 statistical software package, with an independent sample t test for comparison between groups. Descriptive statistics were performed to determine the patient’s diagnostic and clinical features. P-value less than 0.05 were indicated statistically significant.

Results
A total of 1911 patients with non-severe or severe symptoms of COVID-19 during 3 month were admitted in our hospital, of these cases, laboratory diagnosis of 233 patients was confirmed with RT-PCR method. About 12% (28/233) of patients with confirmed diagnosis of this disease were died. Therefore, during the same time, the rate of mortality for all causes in our hospital was 2.04% (39/1911). Of the 233 patients with SARS-CoV-2 infection included in this study, 205 patients were diagnosed as non-severe or severe form of disease (survival group). However, 28 out of 73 who were suffering from severe form of disease, eventually expired (deceased group, [see Table 1]). The mean age of two survival group and deceased group were 47.6 versus 65.3 years, respectively, which was statistically significant different (P < 0.0001). Most of the deceased cases (71.4%) and survival cases (62.9%) were male. Also the mean age of all the patients was 49.8 years.

Clinical and laboratory findings
As indicated in Table 2, fever > 38°C (70%) and dry cough (63%) were the main common symptoms on admission. Dyspnea (62%), SpO2 < %93 (55%) and muscle (32%) or chest (22%) pain were also observed in some patients. Regarding deceased groups, 71% of the infected patients were men (20 cases) and more than half had underlying diseases (16 patients, 64%), including hypertension (seven, 25%), diabetes (six, 21%), renal and cardiovascular disease (three, 11% [Table 3]).

On the admission, lymphopenia (lymphocyte count lower than 1100 μl) (58%), neutrophilia (absolute neutrophil count more than 6300 μl) (25%), and thrombocytopenia (< 125 × 10⁹ per L, 12.4%) were the most principal laboratory abnormalities in our subjects. Regarding survival group, elevated levels of CRP (87.3%), LDH (97.4%), ESR (90.7%), CPK (35%), NLR more than 5 (33.7%), PLR higher than 200 (40.9%), SII index of
rather than 500 (64.9%) were recorded. However, in the deceased group, NLR more than 5, PLR higher than 200 and elevated SII were documented in 93, 71.4 and 93% of the patients, respectively. Furthermore, 79% of deceased patients had lymphopenia. Therefore, NLR, PLR and SII indexes were chosen to be statistically analyzed as the most useful prognostic factor for disease deterioration and severity prediction (Table 4).

Independent sample t test show that the inflammatory indicator levels were significantly elevated in the patients with non-severe or severe COVID-19 (survival group) when compared with the deceased group (NLR; $P < 0.0001$, PLR; $P < 0.001$, SII; $P < 0.0001$) (Table 5). In addition, serum BUN and creatinine levels in group deceased were significantly increased when compared with the survival group ($P < 0.0001$).

### Radiography findings
Radiological data is summarized in Table 6. The typical chest CT patterns of patients with proven COVID-19, were GGO pattern (30.3%), patchy consolidations (11.4%, Fig. 1a) and GGO with consolidations (mixed, 51.2% [see Fig. 1b]). Pure GGO lesions (Fig. 1c, I, II) can be the early appearance of SARS-CoV-2 pneumonia. Ground-glass opacity with consolidation (mixed, 89%) was the most frequently observed radiography finding of the deceased group. Interestingly, 15 (7.1%) of participants had clear chest CT scan findings on admission. Except NLR and SII indicators ($P < 0.01$), there was no statically significant difference in indicators of systemic inflammation of patients who had GGO in comparison with those who had mixed pattern on lung CT (Supplementary Figure 1).

### Discussion
Current study is a descriptive report on the clinical/para-clinical characteristics of 233 patients with laboratory proven evidence of COVID-19 attending BuAli Hospital, Zahedan, Iran. It represents the recent status of the COVID-19 in east of Iran where biggest state of Iran is located. Collectively, 1911 patients who were...
### Table 4: Laboratory test of 233 patients with COVID-19

| Blood routine (Unit, Normal range) | Total number N (%) | Stat         | Total patient N = 233(%) | Survival N = 205 (%) | D ec eased N = 28 (%) |
|-----------------------------------|--------------------|--------------|--------------------------|---------------------|---------------------|
| Leucocyte (x10^9/L, range 3.5–9.5) | 233 (100%)         | Increased    | 37 (15.9%)               | 20 (9.8%)           | 17 (60.7%)          |
|                                   |                    | Decreased    | 27 (11.6%)               | 25 (12.2%)          | 2 (7.1%)            |
|                                   |                    | Normal       | 169 (72.5%)              | 160 (78%)           | 9 (32.2%)           |
| Neutrophil (x10^9/L, range 1.8–6.3) | 233 (100%)         | Increased    | 58 (24.9%)               | 36 (17.6%)          | 22 (78.6%)          |
|                                   |                    | Decreased    | 17 (7.3%)                | 16 (7.8%)           | 1 (3.6%)            |
|                                   |                    | Normal       | 130 (67.8%)              | 153 (74.6%)         | 5 (17.8%)           |
| Lymphocyte (x10^9/L, range 1.1–3.2) | 233 (100%)         | Decreased    | 132 (57.6%)              | 110 (53.7%)         | 22 (78.6%)          |
|                                   |                    | Normal       | 169 (72.5%)              | 160 (78%)           | 9 (32.2%)           |
| Platelet (x10^9/L, range 125–450) | 233 (100%)         | Increased    | 7 (3.1%)                 | 6 (2.9%)            | 1 (3.6%)            |
|                                   |                    | Decreased    | 29 (12.4%)               | 23 (11.2%)          | 6 (21.4%)           |
|                                   |                    | Normal       | 197 (84.5%)              | 176 (85.9%)         | 21 (75%)            |
| D-Dimer (mg/L; range < 0.55)      | 34 (15%)           | Increased    | 19 (55.9%)               | 12 (35.3%)          | 7 (20.6%)           |
|                                   |                    | Normal       | 101 (44.1%)              | 95 (46.7%)          | 0                   |
| ALT (IU/L, range 0–64)            | 202 (87%)          | Increased    | 22 (10.9%)               | 19 (10.6%)          | 3 (13.1%)           |
|                                   |                    | Normal       | 180 (89.1%)              | 160 (89.4%)         | 20 (86.9%)          |
| AST (IU/L, range 8–40)            | 202 (87%)          | Increased    | 74 (36.6%)               | 57 (31.8%)          | 17 (73.9%)          |
|                                   |                    | Normal       | 128 (63.4%)              | 122 (68.2%)         | 6 (26.1%)           |
| ALKP (IU/L, range 25–320)         | 195 (84%)          | Increased    | 36 (18.5%)               | 30 (17.2%)          | 6 (28.6%)           |
|                                   |                    | Normal       | 159 (81.5%)              | 144 (82.8%)         | 15 (71.4%)          |
| Total Bilirubin (mg/dL, range 0.4–1.3) | 180 (77%)         | Increased    | 24 (13.3%)               | 19 (11.8%)          | 5 (26.3%)           |
|                                   |                    | Decreased    | 8 (4.4%)                 | 5 (3.1%)            | 0                   |
|                                   |                    | Normal       | 148 (82.3%)              | 134 (83.1%)         | 14 (73.7%)          |
| Direct Bilirubin (mg/dL, range 0.1–0.3) | 180 (77%)        | Increased    | 73 (40.6%)               | 62 (38.5%)          | 11 (57.9%)          |
|                                   |                    | Decreased    | 36 (20%)                 | 33 (20.5%)          | 3 (15.7%)           |
|                                   |                    | Normal       | 71 (39.4%)               | 66 (41%)            | 5 (26.4%)           |
| Bun (mg/dL, range 5–24)           | 225 (97%)          | Increased    | 59 (26.2%)               | 38 (19.1%)          | 21 (80.8%)          |
|                                   |                    | Normal       | 166 (73.8%)              | 161 (80.9%)         | 5 (19.2%)           |
| Creatinine (mg/dL, range 0.5–1.4) | 223 (96%)          | Increased    | 58 (26%)                 | 40 (20.3%)          | 18 (69.2%)          |
|                                   |                    | Normal       | 165 (74%)                | 157 (79.7%)         | 8 (30.8%)           |
| CPK (IU/L, range 12–160)          | 183 (79%)          | Increased    | 68 (37.2%)               | 57 (35%)            | 11 (55%)            |
|                                   |                    | Normal       | 115 (62.8%)              | 106 (65%)           | 9 (45%)             |
| LDH (IU/L, range 140–280)         | 173 (74%)          | Increased    | 168 (97.1%)              | 151 (97.4%)         | 17 (94%)            |
|                                   |                    | Normal       | 5 (2.9%)                 | 4 (2.6%)            | 1 (6%)              |
| C-Reactive Protein (mg/L, 0.0–6.0) | 233 (100%)         | Increased    | 206 (88.4%)              | 179 (87.3%)         | 27 (96.4%)          |
|                                   |                    | Normal       | 27 (11.6%)               | 26 (12.7%)          | 3 (1.6%)            |
| ESR (mm/h, 2–22)                  | 162 (70%)          | Increased    | 139 (85.8%)              | 124 (90.7%)         | 15 (100%)           |
|                                   |                    | Normal       | 23 (14.2%)               | 23 (9.3%)           | 0                   |
| NA (mEq/L, 135–145)               | 209 (90%)          | Increased    | 7 (3.4%)                 | 3 (1.6%)            | 4 (16%)             |
|                                   |                    | Decreased    | 96 (45.9%)               | 85 (46.2%)          | 11 (44%)            |
| K (mEq/L, 3.5–5.5)                | 208 (90%)          | Increased    | 3 (1.4%)                 | 0                   | 3 (12%)             |
|                                   |                    | Decreased    | 49 (23.6%)               | 43 (23.5%)          | 6 (24%)             |
|                                   |                    | Normal       | 156 (75%)                | 140 (76.5%)         | 16 (64%)            |
suspected to carry the disease were referred to our center over a 3 month period, of which approximately 629 patients had mild/moderate to serious, sometimes fatal, pneumonia and were hospitalized. Given RT-PCR is regarded as reference standard method for diagnosis of SARS-CoV-2 infection [14], the para-clinical data of only 37% (233/629) of patients with positive RT-PCR results were investigated in the present study.

Human coronavirus is one of the main viral pathogens involving respiratory system. SARS-CoV and MERS-CoV besides four other human coronaviruses (HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1) are the main pathogenic viruses belong to coronavirus family causing either severe respiratory syndrome or mild upper respiratory disease [15]. The major SARS-CoV outbreak affected 8422 patients of 29 syndrome or mild upper respiratory disease [15]. The frequency – 2003 [16, 17]. Also, in 2012, MERS-CoV was emerged in Middle East countries [18]. Although, the genomic sequence of SARS-CoV-2 has been shown to be relatively different from the six other coronavirus subtypes but it can be classified as betacoronavirus [15]. In case of SARS-CoV and MERS-CoV, the viruses can be transmitted directly from civets and dromedary camels to humans, respectively, and bats were considered as the origin of both viruses, but the origin of SARS-CoV-2 is still not clear and needs further investigation [15, 19]. Rate of transmission is not exactly documented for SARS-CoV-2; however, human to human transmission has been evidenced [7, 15]. In concert with previous reports, it has been revealed that the clinical manifestations of COVID-19 mimic those presented in SARS-CoV [4, 7, 15, 20]. Fever and cough were the most predominant symptoms manifested in 70% and 63% of our patients, respectively. However, gastrointestinal upsets were infrequently presented (10%), which suggests a different viral tropism and pathogenesis in comparison with SARS-CoV, MERS-CoV, and seasonal influenza [7, 21–23]. The frequency of afebrile patients suffering from COVID-19 (20%) is more frequent than in SARS-CoV (1%) and MERS-CoV infection (2%) [7, 18] implying that presence of fever is not a trustworthy finding to be focused in case definition because afebrile patients will be missed. Similar to previous reports [4, 7, 15], reduced absolute lymphocytes count, and elevated level of CRP and ESR were the main laboratory findings. Damage to T lymphocytes might be a contributing factor leading to substantial decrease in total lymphocytes count and exacerbation of patient’s status [24] as we observed statistically significant abnormalities in laboratory findings (including lymphopenia, elevated NLR, PLR and SII) of patients who expired (deceased group) when compared with survival group. In consistent with our result, a previous study conducted by Liu, et al. [3], documented NLR as the independent risk factor for prediction of severe illness in patients with SARS-CoV-2 infection and should thus have rapid access to an ICU if necessary. So that, in 50% of patients with age ≥ 50 who had NLR ≥ 3.13, severe form of the disease were observed [3, 10]. In another study, a correlation between elevated PLR and the length of hospitalization day was evidenced and it has been concluded that if PLR increased more during treatment, the patient needs longer hospitalization day and had greater possibility of severe pneumonia [25]. Furthermore, Chan et al. in a meta-analysis concluded that NLR and PLR can be served as independent prognostic markers of disease severity in COVID-19 [26]. Recently, NLR and PLR have been validated as prognostic factors in various disorders such as cardiac conditions, solid tumors, sepsis, pneumonia, and ARDS [26]. The SII has been proposed as a prognostic indicator in the follow-up of sepsis patients (Systemic immune inflammatory index in sepsis). In addition, SII has been found to be useful in predicting the prognosis of small cell lung cancer and hepatocellular carcinoma [27, 28]. In consistent with previous study [29], rate of SII was found to be significantly higher in deceased patients when compared with survival group, meaning that it can also be used as predictor of COVID-19 severity and outcome. Therefore, indicators of systemic inflammation such as NLR, PLR and SII may be utilized to predict disease severity, outcome, and mortality of COVID-19. Acute phase proteins such as CRP, LDH, ferritin,
| Blood routine (Unit, Normal range) | Stat       | Total (N = 233) | Mean ±Std. Err. Mean | Sig. (2-tailed) |
|-----------------------------------|------------|-----------------|----------------------|-----------------|
| Leucocyte Count (x10^9/L, range 3.5–9.5) | Deceased 28 | 12.3 ±1.17      | 0.0001**             |
|                                    | Survival   205 | 6.1 ±0.23       |                      |                 |
| Platelet Count (x 10^9/ L, range 125–450) | Deceased 28 | 202.1 ±18.1     | 0.480                |
|                                    | Survival   205 | 215.9 ±6.56     |                      |                 |
| Neutrophil Count (x10^9/ L, range 1.8–6.3) | Deceased 28 | 11.08 ±1.12     | 0.0001**             |
|                                    | Survival   205 | 4.69 ±0.27      |                      |                 |
| Lymphocyte Count (x10^9/ L, range 1.1–3.2) | Deceased 28 | 0.79 ±0.07      | 0.0001**             |
|                                    | Survival   205 | 1.14 ±0.04      |                      |                 |
| Neutrophil / Lymphocyte Ratio (index, < 5) | Deceased 28 | 19.28 ±2.93     | 0.0001**             |
|                                    | Survival   205 | 4.96 ±0.34      |                      |                 |
| Platelet / Lymphocyte Ratio (index, < 200) | Deceased 28 | 343.8 ±66.4     | 0.001*               |
|                                    | Survival   205 | 221.7 ±10.7     |                      |                 |
| Systematic Inflammatory Index (index, < 500) | Deceased 28 | 3532.9 ±565.3   | 0.0001**             |
|                                    | Survival   205 | 1163.5 ±102.9   |                      |                 |
| BUN (mg/dL, range 5–24) | Deceased 26 | 51.2 ±7.18      | 0.0001**             |
|                                    | Survival   199 | 18.3 ±0.65      |                      |                 |
| Creatinine (mg/dL, range 0.5–1.4) | Deceased 26 | 2.22 ±0.28      | 0.0001**             |
|                                    | Survival   197 | 1.16 ±0.02      |                      |                 |
| C-Reactive Protein (mg/L, 0.0–6.0) | Deceased 28 | 15.0 ±0.79      | 0.151                |
|                                    | Survival   205 | 13.2 ±0.44      |                      |                 |
| SGOT (IU/L, range 8–40) | Deceased 23 | 80.1 ±20.2      | 0.0001**             |
|                                    | Survival   179 | 40.6 ±2.43      |                      |                 |
| SGPT (IU/L, range 0–64) | Deceased 23 | 48.8 ±12.1      | 0.176                |
|                                    | Survival   179 | 37.4 ±2.61      |                      |                 |
| Alkaline Phosphatase (IU/L, range 25–320) | Deceased 21 | 271.5 ±17.4     | 0.339                |
|                                    | Survival   174 | 253.1 ±7.76     |                      |                 |
| Total Bilirubin (mg/dL, range 0.4–1.3) | Deceased 19 | 1.44 ±0.31      | 0.004*               |
|                                    | Survival   161 | 0.91 ±0.05      |                      |                 |
| Direct Bilirubin (mg/dL, range 0.1–0.3) | Deceased 19 | 0.59 ±0.21      | 0.007*               |
|                                    | Survival   161 | 0.31 ±0.03      |                      |                 |
| Creatine Kinase (IU/L, range 12–160) | Deceased 20 | 438.8 ±169.3    | 0.315                |
|                                    | Survival   163 | 258.1 ±48.1     |                      |                 |
| Lactate Dehydrogenase (IU/L, range 140–280) | Deceased 18 | 820.5 ±122.1    | 0.001*               |
|                                    | Survival   155 | 534.4 ±26.5     |                      |                 |
| Sodium (mEq/L, 135–145) | Deceased 25 | 136.40 ±1.43    | 0.698                |
|                                    | Survival   184 | 136.04 ±0.28    |                      |                 |
| Potassium (mEq/L, 3.5–5.5) | Deceased 25 | 4.2 ±0.17       | 0.001*               |
|                                    | Survival   183 | 3.9 ±0.03       |                      |                 |
| ESR (mm/h, 2–22) | Deceased 15 | 56.1 ±4.81      | 0.048*               |
|                                    | Survival   147 | 46.3 ±2.17      |                      |                 |
| D-Dimer (mg/L, range < 0.55) | Deceased 7  | 1.24 ±0.06      | 0.001*               |
|                                    | Survival   27  | 0.64 ±0.08      |                      |                 |

The values were presented as mean ± SEM. (*P < 0.05, **P ≤ 0.0001)
procalcitonin, D-Dimer, ESR and IL-6 have also been well correlated with the disease severity, progression and poor outcome in COVID-19 [30]. In our study, CRP protein did not show any significant difference between survival and deceased groups. By the way, pathophysiology of COVID-19 is majorly associated with exaggerated inflammatory responses during the lung involvement. Lymphocytes, especially T lymphocytes, are the main cell to be targeted and consumed by SARS-CoV-2, as does SARS-CoV [24]. Virus particles pass across the respiratory mucosa and attack other cells, resulting in rise of proinflammatory cytokines and stimulate a cytokine storm and a cascade of immune responses in the body, leading to lymphocytic apoptosis, changes in peripheral white blood cells and immune cells such as lymphocytes [15, 31]. In current study, patients who suffered from severe form of COVID-19 (31.3%) required ICU hospitalization and oxygen therapy. Consequently, ARDS and septic shock progressed rapidly in some of our patients, which were eventually followed by multiple organ failure and death. As a result, level of creatinine, BUN and total/direct bilirubin were significantly increased in deceased patients when compared to alive patients which suggesting acute kidney and liver injury in our deceased patients similar to what was evidenced in former report [32]. Therefore, early diagnosis and promptly treatment initiation of critically ill individuals is issue of crucial importance [15]. Only one patient in our investigation was medical worker. The mortality rate of SARS-CoV and MERS-CoV has been reported as more than 10 and 35%, respectively [33, 34]. The rate of mortality in our SARS-CoV-2 infected population was 12%, resembling to previous study [15]. It necessary to be noted that since patients who had uncomplicated illness and who did not need medical attention were not included in our study, the rate of case fatality in a real world scenario might be even lower. COVID-19 was more commonly observed in men than women (64% vs 36%) in our study. This gender preponderance was in agreement with previous studies [4, 7, 15]. Also, higher rate of MERS-CoV and SARS-CoV infection were documented in males than females [35, 36]. The lower frequency rate of COVID-19, MERS-CoV and SARS-CoV infection in females are thought to be attributed to the protection originating from sex hormones and X chromosome, which play contributing role in innate and adaptive immunity [37]. Additionally, it has been documented that COVID-19 is more probably to occur in older adult males due to weaker immune functions particularly those with chronic underlying diseases [15]. Our patient’s age ranged from 16 to 90 years with a mean age of 49.8 years. The data was in consistent with the previous studies which more and less reported similar mean age [7, 15]. The highest positive rate of COVID-19 RT-PCR was observed in age group 40–60 years. Since, our aim was to investigate the COVID-19 patients with positive RT-PCR as reference method, of 629 hospitalized patients who were clinically suspected cases of COVID-19 and also had initial positive CT scan suggesting COVID-19, only small quantity of our subjects had positive RT-PCR assay suggesting two scenarios: first, it may be indeed be true to say that the sensitivity rate of RT-PCR is as low as 37% which somehow has been also demonstrated in previous studies and may be justified by a list of confounding factors which is regarded to influence the result of RT-PCR and lead to false-negative including: improperly collected, transported or handled specimens, presence of amplification inhibitors in the specimen or inadequate numbers of organisms [14, 38, 39]. Second, due to the overlap of CT imaging patterns between COVID-19 and other viral pneumonia, false-positive cases of COVID-19 may be identified on chest CT scan [14]. Nevertheless, given the rapidly spreading of COVID-19, the priority should be to identify and isolate any suspicious CT scan case in order to administer appropriate treatment. By the way, in the context of disease control, some false-positive cases may be acceptable [14]. Therefore, one negative result of RT-PCR does

### Table 6 Radiological data of patients with COVID-19

| Density Pattern | Survival N = 176 (%) | Deceased N = 28 (%) | Lesion Location | No Lesion Count (%) | Right lateral Count (%) | Bilateral Count (%) | Left lateral Count (%) | Total Count (%) |
|-----------------|----------------------|---------------------|----------------|---------------------|-------------------------|-------------------|-----------------------|----------------|
| Clear           | 15 (8.5%)            | 0                   | 15 (7.1%)      | 0                   | 0                      | 0                 | 0                     | 15 (7.1%)      |
| GGO             | 63 (35.8%)           | 0                   | 0              | 22 (10.5%)          | 24 (11.5%)             | 17 (8.3%)         | 23 (11.4%)           | 63 (30.3%)     |
| Consolidation   | 20 (11.4%)           | 3 (10.7%)           | 0              | 5 (2.5%)            | 13 (6.4%)              | 5 (2.5%)          | 23 (11.4%)           | 103 (51.2%)    |
| Mixed           | 78 (44.3%)           | 25 (89.3%)          | 0              | 5 (2.5%)            | 95 (46.9%)             | 3 (1.8%)          | 3 (1.8%)             | 103 (51.2%)    |
| Total           | 176 (100%)           | 28 (100%)           | 15 (7.1%)      | 32 (15.5%)          | 132 (64.8%)            | 25 (12.6%)        | 204 (100%)           |                |
Fig. 1 (See legend on next page.)
not rule out SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions and treatment.

Conclusions
As a result, serially performance of RT-PCR test along with CT scans is recommended. In suspected patients with negative RT-PCR tests, a combination of a history of direct contact with proven cases, clinical manifestations and typical CT imaging features should be collectively used to detect patients with COVID-19. Elevated NLR, PLR and SII can be considered as prognostic and risk stratifying factor of severe form of disease.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-020-05540-3.

Additional file 1: Supplementary Figure 1. Relationship between inflammatory indexes and CT scans pattern.

Abbreviations
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World health organization; ICU: Intensive care unit; ARDS: Acute respiratory distress syndrome; CT: Computed tomography; GGOs: Ground-glass opacities; IL: Interleukin; CRS: Cytokines release syndrome; SNP: Single nucleotide polymorphism; VTM: Virus transport medium; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; LFT: Liver function test; CPK: Creatine phosphokinase; LDH: Lactate dehydrogenase; FAM: Fluorescein amidites; VIC: Victoria; RT-PCR: Real time reverse transcriptase polymerase chain reaction; NLR: Neutrophil to lymphocyte ratio; SII: Systematic immune-inflammation index; PLR: Platelet to lymphocyte ratio; MAS: Macrophage activation syndrome; SHLH: Secondary hemophagocytic lymphohistiocytosis

Acknowledgments
We highly appreciate the cooperation of Immunology laboratory in Buali Hospital.

Authors’ contributions
MR analyzed and interpreted the data, drafted the manuscript and revised the manuscript. SM reviewed the medical records. KA drafted the manuscript. SA and FH analyzed the data. All authors have read and approved the final manuscript for publication.

Funding
This study was financial supported by Zahedan University of Medical Sciences (grant number IRZAUMS.REC.1399.122). The funders had no role in study design, data analysis, or preparation of the manuscript.

Availability of data and materials
The datasets used or analyzed during the current study, as well as the study protocol, are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the ethics committee of Zahedan University of Medical Sciences (IR.ZAU.MS.REC.1399.122) and written consent was obtained from the patients or their guardians.

Consent for publication
Not applicable.

Competing interests
No conflict of interest.

Author details
1Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 3Department of Immunology, Buali Hospital of Laboratory, Zahedan University of Medical Sciences, Zahedan, Iran. 4Infectious Diseases and Tropical Medicine Research Center, Buali Hospital, Zahedan University of Medical Sciences, Zahedan, Iran. 5Rajae Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Received: 8 June 2020 Accepted: 23 October 2020
Published online: 23 November 2020

References
1. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020;92(7):719–25.
2. Banaei M, Ghasemi V, Saei Ghare Naz M, Kiani Z, Rashidi-Fakari F, Banaei S, Mohammad Souri B, Rokni M. Obstetrics and neonatal outcomes in pregnant women with covid-19. A systematic review. Iran J Public Health. 2020;49(3):38–47.
3. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18:1–12.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhuan, China. Lancet. 2020;395(10223):507–13.
5. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-W, He J-X, Liu L, Shan H, Lei C-Y, Hui DS. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020.
6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhuan, China. JAMA. 2020;323(11):1061–9.
7. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-Y, Hui DS. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
8. Ng M-Y, Lee EY, Yang J, Yang F, Li X, Wang H, Lui MM, Lo CS, Leung B, Khong P-L. Imaging profile of the COVID-19 infection: radiologic findings and literature review. Radiology. 2020;202(1):e200334.
9. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388–93.
